Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer research in the Asia-Pacific region, and the importance of clinical trial diversity in this region.
Sarah Anderson
Advertisement
Sarah Anderson is the oncology strategy lead director for Novotech.
Articles by Sarah Anderson
Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer clinical trials in the Asia-Pacific region, and the significant investments being made with novel biomarkers.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
2
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
5
